MD Anderson Cancer Center Offers an Essential 6-Day Course: Mastering Hematology & Oncology for ABIM Success
MD Anderson Cancer Center shared an inviting post on X:
”A virtual live-streaming course will offer comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.”
To learn more and register, follow the link.
A 6-day virtual course by MD Anderson Cancer Center and Baylor College of Medicine offers a comprehensive review of current practices in managing blood disorders and malignancies, tailored to help participants prepare for the ABIM certification in Hematology and Medical Oncology.
The program covers key updates in pharmacology, molecular genetics, risk assessment, and radiation oncology.
By the end of the course, participants will be equipped to:
- Confidently prepare for hematology and medical oncology subspecialty and recertification exams.
- Apply up-to-date standards of care in treating cancer, blood disorders, and malignancies.
- Demonstrate comprehensive knowledge in hematology and medical oncology.
- Integrate recent advances into the management of hematologic and oncologic patients.
Don’t miss your chance, apply now!
Stay informed on the latest conferences, courses, and webinars—read Hemostasis Today for all the updates!
-
Sep 11, 2025, 08:33Alfonso J. Tafur Shares VascuLearn’s Free Virtual Support Groups This Fall for Patients and Providers
-
Sep 10, 2025, 23:00Blood Vessels, Thrombosis and Hemostasis - Blood VTH and Blood Neoplasia: Now Indexed in PubMed!
-
Sep 10, 2025, 13:00Shivani Modi Presents 7 Posters at SOHO 2025: From AI to Hematologic Emergencies
-
Sep 10, 2025, 09:27Deep Vein Thrombosis (DVT) Explained in One Slide: Causes, Symptoms, Diagnosis and Treatment
-
Sep 10, 2025, 09:20Giuseppe Biondi Zoccai Celebrates Release of New Book on Medical Statistics
-
Sep 11, 2025, 15:03Rapid ADAMTS13 Assays: A Key Milestone in the 100 Years of Innvoation in TTP Diagnosis - Silvio Castagni
-
Sep 11, 2025, 13:55Transplantation-Mediated Alloimmune Thrombocytopenia: Mostafa Faisal Mohammed Saleh Presents a Rare Case
-
Sep 10, 2025, 22:34Nicolas Gendron on The Emerging Role of CLIA in The Diagnosis Strategy for HIT
-
Sep 10, 2025, 21:13Gregory Piazza on The Link Between VTE and Atherothrombosis
-
Sep 10, 2025, 19:00Maria Meritxell Roca Mora: DOACs Show Promise Over VKAs in Kidney Transplant Recipients
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births
-
Sep 11, 2025, 08:08Al-Ola A Abdallah on MGUS-Related Bleeding Disorders
-
Sep 10, 2025, 19:32Denis Brutus Oduor: Call for Altruism in Blood Donation in Nairobi
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders